| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/31/2006 | US20060194966 N'-{2-amino-1-(3,5-difluorobenzyl)-3-[(3-; ethylbenzyl)oxy]propyl}-N,N-dipropylisophthalamide; beta-secretase inhibitors; halts or reduces production of A beta peptide from amyloid precursor proteins and reduces or eliminates the formation of beta-amyloid deposits in the brain |
| 08/31/2006 | US20060194962 Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
| 08/31/2006 | US20060194883 Mmp expression inhibitor |
| 08/31/2006 | US20060194882 Adminstering nadolol and carbedilol to treat asthma, emphysema, and chronic obstructive pulmonary diseases; kits |
| 08/31/2006 | US20060194881 Composition comprising at least one alkanolamide to inhibit megration of langerhans cells and uses therof |
| 08/31/2006 | US20060194880 Method for treating central nervous system disorders |
| 08/31/2006 | US20060194879 Pharmaceutically useful salts of carboxylic acid derivates |
| 08/31/2006 | US20060194878 Methods of cardioprotection using dichloroacetate in combination with an inotrope |
| 08/31/2006 | US20060194877 Creatine hydroxycitric acids salts and methods for their production and use in individuals |
| 08/31/2006 | US20060194876 Substantially pure tolterodine tartrate and process for preparing thereof |
| 08/31/2006 | US20060194875 Process for preparation of probucol derivatives |
| 08/31/2006 | US20060194874 Use of propionyl l-carnitine for the preparation of a medicament for the treatment of glaucoma |
| 08/31/2006 | US20060194873 Methods of treating epileptogenesis and epilepsy |
| 08/31/2006 | US20060194872 Diamine derivative, production process therefor and antioxidant |
| 08/31/2006 | US20060194871 Heterocyclic mchr1 antagoists |
| 08/31/2006 | US20060194870 1-((4,14-(Dioxo),5-(1-hydroxy,1,2-dicarboxyethyl)),3-azaoctadec-6-enyl-),4-(phenoxy)benzene derivatives and salts ; extremely potent replication inhibitory activity against the hepatitis C virus (HCV); chronic hepatitis, cirrhosis and liver cancer; mild cytotoxicity in vitro; prophylaxis; prodrugs |
| 08/31/2006 | US20060194869 Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof |
| 08/31/2006 | US20060194868 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and /or congestive heart failure |
| 08/31/2006 | US20060194867 Process for the preparation of atorvastatin and intermediates |
| 08/31/2006 | US20060194866 Less toxicity; side effects redution; substituted p-chlorobenzene and a pyrrolethoxybenzene |
| 08/31/2006 | US20060194865 G-lactam derivatives as prostaglandin agonists |
| 08/31/2006 | US20060194864 Indole derivatives |
| 08/31/2006 | US20060194863 e.g. [(4-Morpholinophenylamino)-methylene]-1,3-dihydro-indol-2-one;tyrosine kinase signal transduction modulators; antiproliferative agents; vision defects, atherosclerosis, restenosis, metabolic disorders, autoimmune diseases |
| 08/31/2006 | US20060194862 respiratory, urinary and gastrointestinal systems disorders; 2-cyclopentyl-2-hydroxy-N-[(3S)-1-benzyl-pyrrolidin-3-yl]-2-phenyl acetamide; side effects reduction; compounds exhibit significant potency |
| 08/31/2006 | US20060194861 e.g. 1-(1-cyclohexyl-5-(4-(methylsulfonyl)phenyl)pyrazol-3-yl)-4-hydroxybutan-1-one; antiinflammatory agent, analgesic, antipyretic, wound healing agents; gastrointestinal disorders; side effect reduction |
| 08/31/2006 | US20060194860 Pharmaceutical compositions containing aryl or heteroaryl azolylcarbinol compounds |
| 08/31/2006 | US20060194859 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity |
| 08/31/2006 | US20060194858 Preparation of crude candesartan cilexetil |
| 08/31/2006 | US20060194857 Anti-diabetic activity, improves insulin resistance and control the blood glucose level more safely, simulates activity of peroxisome proliferator-activated receptor; (1-{(2E)-3-[3-(Bromomethyl)phenyl]prop-2-en-1-yl}-1H-pyrrol-2-yl)(4-methyl-phenyl)methanone |
| 08/31/2006 | US20060194856 Use of atii antagonist for the treatment or prevention of metabolic syndrome |
| 08/31/2006 | US20060194855 Method of treating migraines and pharmaceutical compositions |
| 08/31/2006 | US20060194854 New 2-substituted - 1,3-thiazole compounds |
| 08/31/2006 | US20060194853 Alkyl benzamides |
| 08/31/2006 | US20060194852 Glutaminyl based DPIV inhibitors |
| 08/31/2006 | US20060194851 Benzofuran compound and medicinal composition containing the same |
| 08/31/2006 | US20060194850 methyl 3-(4-{4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-isoxazolyl}-benzylsulfanyl)propionate; compounds inhibit the physiological activity of lysophosphatidic acid (LPA); treatment of fibrosis of organs (liver, kidney, lung, and the like), hepatic disease |
| 08/31/2006 | US20060194848 Substituted amine derivatives and methods of use |
| 08/31/2006 | US20060194847 Novel 6-substituted 2-aminopyridine derivatives |
| 08/31/2006 | US20060194846 neurodegenerative diseases; ischemic stroke, traumatic brain injury, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, senile dementia, spinal cord injury, restless legs syndrome, Huntington's disease, Parkinson's disease, irritable bowel disease and inflammatory bowel diseases, Crohn's disease, |
| 08/31/2006 | US20060194845 Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals |
| 08/31/2006 | US20060194844 2-Acylaminothiazole derivative or salt thereof |
| 08/31/2006 | US20060194843 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections; 4-(2,6-difluoro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methyl-piperidin-4-yl)-amide |
| 08/31/2006 | US20060194842 Oxyindole derivatives |
| 08/31/2006 | US20060194841 Benzylamine derivative |
| 08/31/2006 | US20060194840 Method for treating snoring and sleep apnea with leukotriene antagonists |
| 08/31/2006 | US20060194839 Process for the preparation of Montelukast |
| 08/31/2006 | US20060194838 Polymorphic form of montelukast sodium |
| 08/31/2006 | US20060194837 Tetrahydroisoquinoline compounds |
| 08/31/2006 | US20060194836 Novel compounds having 4-pyridylalkylthio group as substituent |
| 08/31/2006 | US20060194835 Compositions and methods for treating or preventing flaviviridae infections |
| 08/31/2006 | US20060194834 Serotonin receptor antagonist; psychological disorders; Alzheimer's disease |
| 08/31/2006 | US20060194833 Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses |
| 08/31/2006 | US20060194832 Enantiomer (-) of tenatoprazole and the therapeutic use thereof |
| 08/31/2006 | US20060194831 Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| 08/31/2006 | US20060194830 Cyclizing 2,6-diaminopyridine in sulfuric acid with malic acid to form 2-amino-7-hydroxy-1,8-naphthyridine; phthalimidating the naphthyridine and replacing the OH with Cl; reducing the product to form the hydroxyindolinone derivative and etherifying with 5-methyl-2-oxo-hexyltriphenylphosphonium halide |
| 08/31/2006 | US20060194829 Disease of mucous membrane; administering rapamycin or everolimus; topical or mouth administering |
| 08/31/2006 | US20060194828 Vitamin comprising pyroloquinoline quinone and use thereof |
| 08/31/2006 | US20060194827 5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds |
| 08/31/2006 | US20060194826 Pharmaceutical combinations of hydrocodone and naltrexone |
| 08/31/2006 | US20060194825 Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
| 08/31/2006 | US20060194824 Compositions containing pyrimidine derivatives as inhibitors of cox-2 |
| 08/31/2006 | US20060194823 Sulfonamido-macrocycles as Tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof |
| 08/31/2006 | US20060194822 Treatment for renal fibrosis |
| 08/31/2006 | US20060194821 Compounds inhibiting the aggregation of superoxide dismutase-1 |
| 08/31/2006 | US20060194820 administering a drug of 1,5-bis(3-nitrooxypropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, for heart failure and stable angina, cardiovascular disorders |
| 08/31/2006 | US20060194819 Activation specific inhibitors of nf-kb and method of treating inflammatory processes in cardio-vascular diseases |
| 08/31/2006 | US20060194818 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 08/31/2006 | US20060194817 N-{(1S,2R)-1-(3,5-difluorobonzyl)-2-hydroxy-3-[(3-iodobonzyl)amino]propyl}-2-{4-[(methylsulfonyl)amino]phenyl}acetamide; inhibitors of the beta- secretase enzyme useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mamma |
| 08/31/2006 | US20060194816 Benzofuran derivatives useful for treating hyper-proliferative disorders |
| 08/31/2006 | US20060194815 Methods and compositions for modulating serum cortisol levels |
| 08/31/2006 | US20060194814 Benzamide compounds |
| 08/31/2006 | US20060194813 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions |
| 08/31/2006 | US20060194812 Therapy of schizophrenia, Parkinson's disease |
| 08/31/2006 | US20060194811 Pyrimidine derivatives |
| 08/31/2006 | US20060194810 Methods of treating ischemic related conditions |
| 08/31/2006 | US20060194809 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same |
| 08/31/2006 | US20060194808 Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate |
| 08/31/2006 | US20060194807 Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| 08/31/2006 | US20060194806 Optically active 5H-pyrrolo [3,4-b] pyrazine derivative, its preparation and pharmaceutical compositions containing same |
| 08/31/2006 | US20060194805 Capsaicin receptor agonists |
| 08/31/2006 | US20060194804 Hiv replication inhibiting pyrimidines and triazines |
| 08/31/2006 | US20060194803 anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient; to improve learning disorder |
| 08/31/2006 | US20060194802 suc as 5-[4-(2,5-Dichloro-phenoxy)-3-fluoro-phenylamino]-3-hydroxy-N-isopropyl-isothiazole-4-carboxamidine; anticarcinogenic agent |
| 08/31/2006 | US20060194801 inflammation-related conditions in mammals, arthritis, Parkinson's/Alzheimer's diseases, stroke, asthma; acute/chronic or neuropathic pain; VR1 agonist/antagonist; N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-4-((E)-3,3-dimethyl-but-1-enyl)-benzamide; 6-(3,3-Dimethyl-but-1-ynyl)-N-guinolin-3-yl-nicotinamide |
| 08/31/2006 | US20060194800 Pteridine derivatives as nitric oxide synthase activators |
| 08/31/2006 | US20060194799 Novel pyrimidinedione derivatives |
| 08/31/2006 | US20060194798 Bicyclic-substituted amines as histamine-3 receptor ligands |
| 08/31/2006 | US20060194797 Condensed ring compound and use thereof |
| 08/31/2006 | US20060194796 Method of treatment for preventing or reducing tumor growth in the liver of patient |
| 08/31/2006 | US20060194795 Platelet ADP receptor inhibitors |
| 08/31/2006 | US20060194794 oxadiazoles such as 2-({[5-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-[1,3,4]oxadiazol-2-ylmethyl]-amino}-methyl)-phenylamine exhibiting vasopressin antagonistic activity and can be used in the treatment of dysmenorrhea |
| 08/31/2006 | US20060194793 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 08/31/2006 | US20060194792 1-Cyclic carbonyl-4-(4-quinoline-)-1,4-diazepine or 1-cyclic carbonyl-4-[4-(1H-quinolin-2-{thio}one)-1,4-diazepinone derivatives; retinopathy, adult respiratory distress syndrome, asthma, osteoarthritis, glomerulonephritis, psoriasis, rheumatoid arthritis, and toxic shock syndrome treatment |
| 08/31/2006 | US20060194791 Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders |
| 08/31/2006 | US20060194790 Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists |
| 08/31/2006 | US20060194789 Fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof |
| 08/31/2006 | US20060194788 N-(5-ethyl-5-methyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine or its formate, suitable for the treatment of pain and hyperalgesia |
| 08/31/2006 | US20060194787 substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation |
| 08/31/2006 | US20060194786 Process and intermediates for preparing benzazepines |
| 08/31/2006 | US20060194785 Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof |